Cargando…

Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)

The purpose of this study was to identify the incidence, causes and impact of non-adherence to oral and subcutaneous chronic treatments for patients with polycythemia vera or essential thrombocythemia. Patients receiving cytoreductive drugs for polycythemia vera or essential thrombocythemia were rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Calloch, Ronan, Lacut, Karine, Le Gall-Ianotto, Christelle, Nowak, Emmanuel, Abiven, Morgane, Tempescul, Adrian, Dalbies, Florence, Eveillard, Jean-Richard, Ugo, Valérie, Giraudier, Stéphane, Guillerm, Gaëlle, Lippert, Eric, Berthou, Christian, Ianotto, Jean-Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865440/
https://www.ncbi.nlm.nih.gov/pubmed/29246923
http://dx.doi.org/10.3324/haematol.2017.180448
_version_ 1783308682447028224
author Le Calloch, Ronan
Lacut, Karine
Le Gall-Ianotto, Christelle
Nowak, Emmanuel
Abiven, Morgane
Tempescul, Adrian
Dalbies, Florence
Eveillard, Jean-Richard
Ugo, Valérie
Giraudier, Stéphane
Guillerm, Gaëlle
Lippert, Eric
Berthou, Christian
Ianotto, Jean-Christophe
author_facet Le Calloch, Ronan
Lacut, Karine
Le Gall-Ianotto, Christelle
Nowak, Emmanuel
Abiven, Morgane
Tempescul, Adrian
Dalbies, Florence
Eveillard, Jean-Richard
Ugo, Valérie
Giraudier, Stéphane
Guillerm, Gaëlle
Lippert, Eric
Berthou, Christian
Ianotto, Jean-Christophe
author_sort Le Calloch, Ronan
collection PubMed
description The purpose of this study was to identify the incidence, causes and impact of non-adherence to oral and subcutaneous chronic treatments for patients with polycythemia vera or essential thrombocythemia. Patients receiving cytoreductive drugs for polycythemia vera or essential thrombocythemia were recruited at our institution (Observatoire Brestois des Néoplasies Myéloprolifératives registry). They completed a one-shot questionnaire designed by investigators (Etude de l’Observance Thérapeutique et des Effets Secondaires des Traitements study). Data about complications (thrombosis, transformation and death) at any time in the patient’s life (before diagnosis, up until consultation and after the completion of the questionnaire) were collected. Sixty-five (22.7%) of 286 patients reported poor adherence (<90%) to their treatment with cytoreductive drugs and 46/255/18%) also declared non-adherence to antithrombotic drugs. In total, 85/286 patients (29.7%) declared they did not adhere to their treatment. Missing an intake was rare and was mostly due to forgetfulness especially during occupational travel and holidays. Patients who did not adhere to their treatment were characterized by younger age, living alone, having few medications but a high numbers of pills and determining their own schedule of drug intake. Having experienced thrombosis or hematologic evolution did not influence the adherence rate. Non-adherence to oral therapy was associated with a higher risk of phenotypic evolution (7.3 versus 1.8%, P=0.05). For patients treated for polycythemia vera or essential thrombocythemia, non-adherence to cytoreductive and/or antithrombotic therapies is frequent and is influenced by age, habitus and concomitant treatments, but not by disease history or treatment side effects. Phenotypic evolution seems to be more frequent in the non-adherent group.
format Online
Article
Text
id pubmed-5865440
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Ferrata Storti Foundation
record_format MEDLINE/PubMed
spelling pubmed-58654402018-04-01 Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study) Le Calloch, Ronan Lacut, Karine Le Gall-Ianotto, Christelle Nowak, Emmanuel Abiven, Morgane Tempescul, Adrian Dalbies, Florence Eveillard, Jean-Richard Ugo, Valérie Giraudier, Stéphane Guillerm, Gaëlle Lippert, Eric Berthou, Christian Ianotto, Jean-Christophe Haematologica Article The purpose of this study was to identify the incidence, causes and impact of non-adherence to oral and subcutaneous chronic treatments for patients with polycythemia vera or essential thrombocythemia. Patients receiving cytoreductive drugs for polycythemia vera or essential thrombocythemia were recruited at our institution (Observatoire Brestois des Néoplasies Myéloprolifératives registry). They completed a one-shot questionnaire designed by investigators (Etude de l’Observance Thérapeutique et des Effets Secondaires des Traitements study). Data about complications (thrombosis, transformation and death) at any time in the patient’s life (before diagnosis, up until consultation and after the completion of the questionnaire) were collected. Sixty-five (22.7%) of 286 patients reported poor adherence (<90%) to their treatment with cytoreductive drugs and 46/255/18%) also declared non-adherence to antithrombotic drugs. In total, 85/286 patients (29.7%) declared they did not adhere to their treatment. Missing an intake was rare and was mostly due to forgetfulness especially during occupational travel and holidays. Patients who did not adhere to their treatment were characterized by younger age, living alone, having few medications but a high numbers of pills and determining their own schedule of drug intake. Having experienced thrombosis or hematologic evolution did not influence the adherence rate. Non-adherence to oral therapy was associated with a higher risk of phenotypic evolution (7.3 versus 1.8%, P=0.05). For patients treated for polycythemia vera or essential thrombocythemia, non-adherence to cytoreductive and/or antithrombotic therapies is frequent and is influenced by age, habitus and concomitant treatments, but not by disease history or treatment side effects. Phenotypic evolution seems to be more frequent in the non-adherent group. Ferrata Storti Foundation 2018-04 /pmc/articles/PMC5865440/ /pubmed/29246923 http://dx.doi.org/10.3324/haematol.2017.180448 Text en Copyright© 2018 Ferrata Storti Foundation Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.
spellingShingle Article
Le Calloch, Ronan
Lacut, Karine
Le Gall-Ianotto, Christelle
Nowak, Emmanuel
Abiven, Morgane
Tempescul, Adrian
Dalbies, Florence
Eveillard, Jean-Richard
Ugo, Valérie
Giraudier, Stéphane
Guillerm, Gaëlle
Lippert, Eric
Berthou, Christian
Ianotto, Jean-Christophe
Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)
title Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)
title_full Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)
title_fullStr Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)
title_full_unstemmed Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)
title_short Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)
title_sort non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (ouest study)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865440/
https://www.ncbi.nlm.nih.gov/pubmed/29246923
http://dx.doi.org/10.3324/haematol.2017.180448
work_keys_str_mv AT lecallochronan nonadherencetotreatmentwithcytoreductiveandorantithromboticdrugsisfrequentandassociatedwithanincreasedriskofcomplicationsinpatientswithpolycythemiaveraoressentialthrombocythemiaoueststudy
AT lacutkarine nonadherencetotreatmentwithcytoreductiveandorantithromboticdrugsisfrequentandassociatedwithanincreasedriskofcomplicationsinpatientswithpolycythemiaveraoressentialthrombocythemiaoueststudy
AT legallianottochristelle nonadherencetotreatmentwithcytoreductiveandorantithromboticdrugsisfrequentandassociatedwithanincreasedriskofcomplicationsinpatientswithpolycythemiaveraoressentialthrombocythemiaoueststudy
AT nowakemmanuel nonadherencetotreatmentwithcytoreductiveandorantithromboticdrugsisfrequentandassociatedwithanincreasedriskofcomplicationsinpatientswithpolycythemiaveraoressentialthrombocythemiaoueststudy
AT abivenmorgane nonadherencetotreatmentwithcytoreductiveandorantithromboticdrugsisfrequentandassociatedwithanincreasedriskofcomplicationsinpatientswithpolycythemiaveraoressentialthrombocythemiaoueststudy
AT tempesculadrian nonadherencetotreatmentwithcytoreductiveandorantithromboticdrugsisfrequentandassociatedwithanincreasedriskofcomplicationsinpatientswithpolycythemiaveraoressentialthrombocythemiaoueststudy
AT dalbiesflorence nonadherencetotreatmentwithcytoreductiveandorantithromboticdrugsisfrequentandassociatedwithanincreasedriskofcomplicationsinpatientswithpolycythemiaveraoressentialthrombocythemiaoueststudy
AT eveillardjeanrichard nonadherencetotreatmentwithcytoreductiveandorantithromboticdrugsisfrequentandassociatedwithanincreasedriskofcomplicationsinpatientswithpolycythemiaveraoressentialthrombocythemiaoueststudy
AT ugovalerie nonadherencetotreatmentwithcytoreductiveandorantithromboticdrugsisfrequentandassociatedwithanincreasedriskofcomplicationsinpatientswithpolycythemiaveraoressentialthrombocythemiaoueststudy
AT giraudierstephane nonadherencetotreatmentwithcytoreductiveandorantithromboticdrugsisfrequentandassociatedwithanincreasedriskofcomplicationsinpatientswithpolycythemiaveraoressentialthrombocythemiaoueststudy
AT guillermgaelle nonadherencetotreatmentwithcytoreductiveandorantithromboticdrugsisfrequentandassociatedwithanincreasedriskofcomplicationsinpatientswithpolycythemiaveraoressentialthrombocythemiaoueststudy
AT lipperteric nonadherencetotreatmentwithcytoreductiveandorantithromboticdrugsisfrequentandassociatedwithanincreasedriskofcomplicationsinpatientswithpolycythemiaveraoressentialthrombocythemiaoueststudy
AT berthouchristian nonadherencetotreatmentwithcytoreductiveandorantithromboticdrugsisfrequentandassociatedwithanincreasedriskofcomplicationsinpatientswithpolycythemiaveraoressentialthrombocythemiaoueststudy
AT ianottojeanchristophe nonadherencetotreatmentwithcytoreductiveandorantithromboticdrugsisfrequentandassociatedwithanincreasedriskofcomplicationsinpatientswithpolycythemiaveraoressentialthrombocythemiaoueststudy